Sugi Predict

Sugi Predict / Targets / GLI2

GLI2

Zinc finger protein GLI2 · P10070 · GLI2 on Sugi Atlas →

2,025 patent compounds predicted against GLI2, 1,422 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL7095668 SCHEMBL7095668 0.52 5/20
SCHEMBL10420237 SCHEMBL10420237 0.56 3/20
Ketoprofen Ketoprofen (SCHEMBL4875918) 0.56 3/20
Ketoprofen Ketoprofen (SCHEMBL572766) 0.53 3/20
Ketoprofen Ketoprofen (SCHEMBL2286417) 0.53 3/20
Ketoprofen Ketoprofen (SCHEMBL9844958) 0.53 3/20
SCHEMBL4463228 SCHEMBL4463228 0.53 3/20
SCHEMBL4463231 SCHEMBL4463231 0.53 3/20
SCHEMBL5494432 SCHEMBL5494432 0.49 3/20
SCHEMBL6381046 SCHEMBL6381046 0.49 3/20
Ketoprofen Ketoprofen (SCHEMBL4487212) 0.48 3/20
SCHEMBL5499383 SCHEMBL5499383 0.48 3/20
SCHEMBL10421105 SCHEMBL10421105 0.47 3/20
SCHEMBL2687554 SCHEMBL2687554 0.47 3/20
Ketoprofen Ketoprofen (SCHEMBL4300662) 0.47 3/20
R-Ketoprofen R-Ketoprofen (SCHEMBL4300669) 0.47 3/20
SCHEMBL4048934 SCHEMBL4048934 0.46 3/20
SCHEMBL2687556 SCHEMBL2687556 0.46 3/20
SCHEMBL4483488 SCHEMBL4483488 0.46 3/20
SCHEMBL9057032 SCHEMBL9057032 0.44 3/20

Clinical trials — most relevant to GLI2 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus. PHASE3COMPLETED
Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase PHASE3UNKNOWN
Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer PHASE2COMPLETED
Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial PHASE1/PHASE2RECRUITING
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome PHASE2WITHDRAWN
Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma PHASE2COMPLETED
Open-label Trial of SUBA™-Itraconazole (SUBA-Cap) in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS) PHASE2COMPLETED
Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer PHASE2COMPLETED
GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery PHASE2COMPLETED
Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas PHASE1/PHASE2COMPLETED
Phase 2 Study of IDH305 in Low Grade Gliomas PHASE2WITHDRAWN
Study of LDE225 (Sonidegib) in Combination With Docetaxel in Triple Negative (TN) Advanced Breast Cancer (ABC) Patients PHASE1COMPLETED
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC) PHASE1COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma PHASE1RECRUITING
FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma PHASE1COMPLETED
GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment PHASE1COMPLETED
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma PHASE1COMPLETED
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma PHASE1COMPLETED
A Study of Vismodegib in Men With Metastatic CRPC With Accessible Metastatic Lesions for Tumor Biopsy EARLY_PHASE1COMPLETED
Effect on Tumor Perfusion of a Chemotherapy Combining Gemcitabine and Vismodegib Before Surgery in Pancreatic Cancer EARLY_PHASE1UNKNOWN
Topical Itraconazole in Treating Patients With Basal Cell Cancer EARLY_PHASE1COMPLETED
Mapping of Tumor Stem Cells in the Resection Marigin During Extirpation of Highly Malignant Gliomas Using GlioStem nanUNKNOWN
MR Elastography in Intracranial Lesions: Feasibility & Accuracy nanACTIVE_NOT_RECRUITING
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors nanUNKNOWN
DNA Methylation and Autoimmune Thyroid Diseases nanCOMPLETED
HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) nanUNKNOWN
Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT) nanCOMPLETED
Use Of Oral Itraconazole In Patients With Locally Limited Basocellular Carcinoma Of Skin. nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a GLI2 binder may also engage these)

ProteinNameSimilarity
Q0VGT2 — 1.000 Q0VGT2 →
Q9VQ56 — 0.997 Q9VQ56 →
Q7TQ40 — 0.996 Q7TQ40 →
P55878 — 0.994 P55878 →
Q9Z1J1 — 0.994 Q9Z1J1 →
Q91660 — 0.994 Q91660 →
Q6YHU8 — 0.994 Q6YHU8 →
Q05B92 — 0.994 Q05B92 →
Q9HCS4 — 0.993 Q9HCS4 →
O09100 — 0.993 O09100 →
Q9QYE3 — 0.993 Q9QYE3 →
P25932 — 0.993 P25932 →
Q99958 — 0.993 Q99958 →
Q68F77 — 0.993 Q68F77 →
Q91661 — 0.993 Q91661 →
P08152 — 0.993 P08152 →
Q61850 — 0.993 Q61850 →
Q92858 — 0.993 Q92858 →
GLI1 Zinc finger protein GLI1 0.992 landscape →
P28166 — 0.992 P28166 →
Q95JA5 — 0.992 Q95JA5 →
P47806 — 0.992 P47806 →
Q04888 — 0.992 Q04888 →
Q62255 — 0.992 Q62255 →
P23769 — 0.992 P23769 →
P06602 — 0.992 P06602 →
P81067 — 0.992 P81067 →
P81068 — 0.992 P81068 →
O95096 — 0.992 O95096 →
Q95RW8 — 0.992 Q95RW8 →